Siddhi Choure’s Post

🔬 Exciting News: CRISPR Gets FDA Nod for Treating Beta Thalassemia! What does this mean for Cancer?🧬 Last week marked a milestone with the FDA approving CRISPR gene-editing for transfusion-dependent beta thalassemia—the second major U.S. approval for this cutting-edge technology. 🌐👏 🌟 Cancer & Oncology Implications: Beyond blood disorders, CRISPR's success extends to cancer research. Recent trials demonstrate its potential in editing T cells, boosting antitumor immunity, and advancing personalized cancer treatments. A leap forward in precision medicine! 💪🌈 🚀 Revolutionizing Cancer Therapies: Precise T cell editing using CRISPR opens new doors in immunotherapy, enhancing treatment efficacy and paving the way for more targeted approaches. A game-changer in the fight against cancer. 🎯💉 🧬 Next Frontier in Precision Medicine: As we celebrate CRISPR's success, we anticipate its transformative impact on cancer treatment. From refining diagnostics to allogeneic T cell immunotherapy, CRISPR is reshaping healthcare with vast potential applications. 🌟🔍 Kudos to the researchers driving this medical revolution! Here's to a future where CRISPR continues to redefine healthcare. 💙🌐 #CRISPR #PrecisionMedicine #MedicalInnovation #CancerResearch #HealthcareRevolution #GeneEditing https://lnkd.in/gvZqSayh

In a groundbreaking study published in Springer Nature Group's Nature Cell Biology, researchers from the Mass General Cancer Center have identified a gene that plays a pivotal role in the spread of cancer cells throughout the body. This gene, known as Gstt1, is crucial for metastatic cancer cells to modify their environment and thrive in new locations. 🧬 The study reveals that Gstt1 encodes an enzyme part of a superfamily that protects cells from toxins. More importantly, it allows cancer cells to alter and secrete fibronectin, a protein essential for cell attachment to the extracellular matrix. 🎯 Silencing the Gstt1 gene in lab models prevented metastatic growth, offering a beacon of hope for new treatment strategies, particularly for pancreatic cancer patients who often face a diagnosis at the metastatic stage. 💡 This discovery is not just a scientific triumph but a potential lifesaver. It underscores the importance of persistent research and innovation in the battle against cancer. 🤝 Join us in applauding the Mass General Cancer Center team for their dedication and breakthrough that may pave the way for novel therapeutic avenues targeting metastatic cancer, which is responsible for 90% of cancer-related deaths. cc: Dr. Jessica Lin, Dr. Justin Gainor #CancerResearch #Metastasis #Genetics #Innovation #Healthcare #ScienceNews https://lnkd.in/dH5yBKrM

Colorectal cancer (CRC) is a leading cause of cancer mortality, driven by genetic and environmental factors. Genomics and differential expression analysis offer crucial insights into CRC's molecular mechanisms, aiding in #personalizedmedicine approaches. Our latest use case demonstrates how g.nome® simplifies complex #omics analysis, enabling researchers and clinicians to effortlessly conduct differential gene expression studies. By leveraging publicly available #RNAseq datasets from the Sequence Read Archive (SRA), we uncover novel genetic insights, driving future CRC research and therapeutic strategies. See how we identified potential biomarkers for early detection and prognosis of CRC, spotlighting key genes like KRT23 and ETV4. Our streamlined approach reduces technical barriers, allowing you to quickly derive meaningful insights from complex data. Read the full use case: https://lnkd.in/gkd6tRKT

Role of Gene fusions in the development of the cancer . One of the crucial aspects of creating a personalised medicine for a patient is determining the full genetic profile of a patient. • Gene fusions play a major role in understanding the development of cancer or oncogenesis. • Gene fusions or translocations have the potential to create chimeric proteins with altered function. •These events may also rearrange gene promoters to amplify oncogenic function through protein overexpression or to decrease the expression of tumour suppressor genes What are Gene fusions all about?? • Gene fusions are the hybrid genes that form when a gene breaks off from a chromosome and joins with an unrelated gene either on the same or different chromosome, which results in the formation of abnormal protein which can promote tumour growth. • Some well-known fusion genes include BCR-ABL1, ETV6-NTRK3, and TMPRSS2-ETS, which have been shown to have a direct impact on tumour development and function. .To give an instance, a frequent translocation between chromosomes 11 and 22 has been found which creates a fusion between EWSR1 and FLI1 in Ewing’s sarcoma. . While, on the other hand, The Philadelphia chromosome 9–22 translocation has been observed in chronic myeloid leukaemia, resulting in the fusion protein BCR–ABL1. • This fusion leads to constitutive protein tyrosine kinase activity and downstream signalling of the PI3K and MAPK pathways, which enables cells to inhibit apoptosis and achieve increased cell proliferation. Picture courtesy: BC Cancer MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center Cancer Science Institute of Singapore The Institute of Cancer Research References https://lnkd.in/gdtZqFkz #Genomics #PrecisionMedicine #CancerResearch #GeneFusions #Oncogenesis #PersonalizedMedicine #ChimericProteins #TumorDevelopment #Translocations #MolecularBiology #MedicalResearch #EwingSarcoma #LeukemiaResearch #MedicalInnovation #Chromosome #BCRABL1 #ETV6NTRK3 #TMPRSS2ETS

【Scientific Breakthrough】Researchers have developed a computational tool named CAVE that identifies low-burden variants in TP53 gene from Next-Generation Sequencing (NGS) data in Chronic Lymphocytic Leukemia (CLL). This tool can detect specific variants with variant allele frequencies (VAF) as low as 0.3%, helping to distinguish true variants from background noise. The study indicates that low-VAF TP53 variants are common in CLL and closely related to tumor heterogeneity. The development of CAVE offers new insights for clinical detection and treatment decisions, potentially improving outcomes for patients with CLL. For more details, refer to Scientific Reports, Volume 14, 2024. 🎉 🎉 Our company offers a range of solutions for low-frequency mutation analysis, including the introduction of molecular tag adapters and the use of Nanda's exclusive patented Panel for hybrid capture. These enable the detection of tumor mutation sites using circulating tumor DNA from cancer patients' plasma, the detection of fetal monogenic diseases using circulating free DNA from pregnant mothers' plasma, and the detection of MRD in hematologic tumors using blood genomic DNA. For more details, please visit our official website： The full text link: https://lnkd.in/gTsSqwZB #CancerResearch #GeneVariants #CAVETool #CLL #TP53

𝗪𝗲 𝘀𝘁𝗶𝗹𝗹 𝗱𝗼𝗻'𝘁 𝗸𝗻𝗼𝘄 𝗺𝘂𝗰𝗵 𝗮𝗯𝗼𝘂𝘁 𝗺𝗶𝗥𝗡𝗔 𝗯𝗶𝗼𝗹𝗼𝗴𝘆! 🧬 Recent research continues to reveal just how complex and mysterious miRNA biology really is. Here are some key takeaways from a 𝗿𝗲𝗰𝗲𝗻𝘁 𝘀𝘁𝘂𝗱𝘆 𝗼𝗻 𝗺𝗶𝗰𝗿𝗼𝗥𝗡𝗔 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗮𝗹 𝗱𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆 in early-stage lung adenocarcinoma: 𝗠𝗶𝗰𝗿𝗼𝗥𝗡𝗔𝘀 𝗶𝗻 𝟯𝗗: Beyond their traditional role in gene regulation, microRNAs can have different sequence and structural forms (isomiRs) that add layers of complexity to their function. 𝗗𝗶𝘃𝗲𝗿𝘀𝗲 𝘀𝗲𝗾𝘂𝗲𝗻𝗰𝗲, 𝗱𝗶𝘃𝗲𝗿𝘀𝗲 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲, 𝗱𝗶𝘃𝗲𝗿𝘀𝗲 𝗳𝘂𝗻𝗰𝘁𝗶𝗼𝗻: The study found that microRNAs are not uniform; slight variations in their sequences can drastically change their target interactions and biological roles. This diversity plays a crucial role in cancer progression. 𝗜𝗚𝗙𝟮𝗕𝗣𝟯 𝗽𝗿𝗼𝘁𝗲𝗶𝗻: The study highlights how the oncofetal protein IGF2BP3 controls the structural diversity of microRNAs (generating 1-nucleotide shorter miR-21!!) influencing cancer cell behavior. This protein was found to be a key player in malignancy, particularly in early-stage lung adenocarcinoma. 𝗜𝗺𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀: Understanding the sequence/structural diversity of microRNAs could open new avenues for targeted cancer therapies. It suggests that the specific forms of microRNAs present in a tumor could impact the effectiveness of treatments. If we want to unlock new diagnostic and therapeutic potentials, we need to 𝗱𝗲𝗹𝘃𝗲 𝗱𝗲𝗲𝗽𝗲𝗿 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗮𝗹 𝗻𝘂𝗮𝗻𝗰𝗲𝘀 𝗼𝗳 𝗺𝗶𝗰𝗿𝗼𝗥𝗡𝗔𝘀. 🔗 Read the full study here: https://lnkd.in/dT8T3up7

Our latest article is online! The mitochondrial DNA common deletion is a large-scale deletion removing key genes involved in mitochondrial functions, leading to severe human conditions. By analysing the mitochondrial DNA from patient-derived skin cancer-associated fibroblasts (known as CAFs) and normal fibroblasts, we consistently found different deletion amounts in these two skin cells populations. Such diverse deletion content generates a peculiar mitochondrial DNA gene expression pattern that we found to be present in independently-collected single-cell RNA sequencing data from skin cancer patients. Our findings could boost the development of novel biomarkers to identify cancer-associated fibroblasts, leading to potential therapeutic benefits. Thanks to all collaborators for making this research possible: it was a wonderful experience to work with you all and an honour to share this experience! Check the full article here: https://lnkd.in/e_SvAxGN #mitochondria   #mitochondrialDNA #cancerresearch #biomarkers #biomarkerdiscovery #tumormicroenvironment

Tumor purity - a gene expression-based approach to determining “In this study, we exploited over 6000 samples from 10 breast cancer datasets to systematically quantify the impact of intrinsic and extrinsic factors on cellularity and to generate and validate a Breast Cancer Purity Score (BCPS). BCPS outperformed ESTIMATE in quantifying tumour purity and can be successfully used to adjust for tumour purity variability when extrinsic factors are prevalent. BCPS can also capture treatment-induced changes carrying predictive and prognostic information.” #tumorpurity #geneexpression #breastcancer

It is now online! Together with American and European researchers, we analyzed data from three clinical trials involving 1289 early breast cancer patients with ERBB2/HER2-positive tumors. We found that the association between treatment response and survival varied by tumor subtype. Notably, the combination of trastuzumab and lapatinib showed significant survival benefits, especially in ERBB2-enriched tumors. Immune-related gene expression signatures emerged as crucial factors, being linked to treatment response and improved survival outcomes, highlighting the importance of tailoring treatment based on molecular characteristics. https://lnkd.in/dsX9yR8F

Reflecting on World Cancer Day 🎗, I am happy to share that our #multiomics method in #ovariancancer, quantifying the copy-number alterations impact on gene expression has been published today in BMC Cancer! 🎆 This project has been a pivotal part of my PhD journey. We have identified several pathways strongly affected by copy-number alterations and six of them were associated with patient survival. Our results also suggest that wild-type KRAS-induced chemoresistance is a putative cause for the shortened response to #chemotherapy in a group of #ovariancancer patients with high KRAS expression. Thanks to the great team who did this together as a part of DECIDER Project. Together, we contribute to the ongoing fight against cancer. 💪 https://lnkd.in/ddUVgCXF